Composition for treating hyperlipemia

A technology for hyperlipidemia and composition, applied in the new composition field, can solve the problem of not disclosing the optimal ratio of axiolimus and simvastatin compound pharmacological experimental data, etc.

Inactive Publication Date: 2005-10-05
SHANDONG NEWTIME PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Chinese patent application CN1425374A discloses the composition of acipimox and lovastatin, the disclosed ratio is that the weight ratio of acipimox and lovastatin is 25~50

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0015] Example 1

[0016] a, Acipimox 200g

[0017] Blank pellet core 250g

[0018] 7% PVP solution (90% ethanol solvent) 200g

[0019] Preparation process: Pass acipimox through a 120-mesh sieve, weigh the prescription, and pour it into the lower hopper. Open the granulation coating machine, the inlet pressure is 0.5bar, the inlet temperature is 30℃, the spray gun pressure (CYL) is 3bar, the atomization pressure (CAP1) is 0.8bar, pour into the blank pellet core, granulate, the feeding speed is 4rpm, creeping Pump 12%, turntable speed 145rpm, spray 7% PVP solution (solvent is 90% ethanol). After granulation is finished, it is dried at 50℃ and discharged.

[0020] b. Simvastatin 5g

[0021] Blank pellet core 30g

[0022] 7% PVP solution (solvent is 90% ethanol) 30g

[0023] Preparation process: Pass simvastatin through a 120-mesh sieve, weigh the prescription, and pour it into the lower hopper. Open the granulation coating machine, the inlet pressure is 0.5...

Example Embodiment

[0025] Example 2

[0026] a, Acipimox 200g

[0027] Lactose 30g

[0028] Sodium Carboxymethyl Starch 30g

[0029] Microcrystalline cellulose 18g

[0030] 6% PVP in anhydrous ethanol solution 100g

[0031] Magnesium stearate 2g

[0032] Preparation process: axiolimus is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through an 80-mesh sieve, and the prescribed amount of aximus, lactose, sodium carboxymethyl starch, and microcrystalline fiber are weighed. Mix the ingredients uniformly, add 6% PVP anhydrous ethanol solution for granulation, dry at 60°C, and sieve the dry granules with a 16 mesh sieve. Add the prescribed amount of magnesium stearate to the dry granules.

[0033] b. Simvastatin 10g

[0034] Hydroxypropyl cellulose 15g

[0035] Pregelatinized starch 10g

[0036] 6% PVP in anhydrous ethanol solution 30g

[0037] Glyceryl behenic acid 1g

[0038] Preparation process:...

Example Embodiment

[0040] Example 3

[0041] a, Acipimox 200g

[0042] Lactose 30g

[0043] Sodium Carboxymethyl Starch 30g

[0044] Microcrystalline cellulose 18g

[0045] 6% PVP in anhydrous ethanol solution 100g

[0046] Magnesium stearate 2g

[0047] Preparation process: axiolimus is passed through a 100-mesh sieve, lactose, sodium carboxymethyl starch, and microcrystalline cellulose are passed through an 80-mesh sieve, and the prescribed amount of aximus, lactose, sodium carboxymethyl starch, and microcrystalline fiber are weighed. Mix the ingredients uniformly, add 6% PVP anhydrous ethanol solution for granulation, dry at 60°C, and sieve the dry granules through a 16-mesh sieve. Add the prescribed amount of magnesium stearate to the dry granules.

[0048] b. Simvastatin 20g

[0049] Hydroxypropyl cellulose 30g

[0050] Pregelatinized starch 20g

[0051] 6% PVP in anhydrous ethanol solution 50g

[0052] Glycerol behenate 2g

[0053] Prepara...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a new drug treatment composition for treating hyperlipidemia, which is charactered in that it contains an effective volume of Acipimox and Simvastatin, and it has a weight ratio of (10 ~ 80): 1, a preferable weight ratio of (10 ~ 40): 1, and further preferable weight ratio of 15:1. Its lipid-lowering effect is superior to the same dose of signal prescription, which indicates the two drugs have synergistic effects, and at the same time have no obvious toxicity.

Description

Technical field [0001] The invention relates to a new composition for treating hyperlipidemia, especially a composition containing acipimox, simvastatin and pharmaceutical auxiliary materials. Background technique [0002] With the continuous development of medical science, people realize that the high content of cholesterol and fat is the basic cause of cardiovascular disease, and hyperlipidemia is the main risk factor of coronary heart disease and hypertension. Therefore, people began to focus on the development of blood lipid regulating drugs as the prevention and treatment of cardiovascular diseases. Since the late 1980s, a large number of blood lipid-lowering drugs have been launched, among which statins have been well received by people, and their clinical efficacy is unmatched by other types of blood lipid regulating drugs. Over the past ten years, the completion of several international large-scale coronary heart disease prevention and treatment trials has confirmed...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4965A61P3/06
Inventor 赵志全
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap